Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors

Published:2021-05 Issue: Volume:Volume 14 Page:2929-2939
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Li Chao,Li Xujun

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference97 articles.

1. Globocan. Breast cancer fact sheet; 2018. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed November 16, 2020.

2. Institute NC. Cancer Stat facts: female breast cancer. 2019; Available from: https://seer.cancer.gov/statfacts/html/breast.html. Accessed November 16, 2020.

3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

4. Over surgery in breast cancer

5. Breast cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review;Targeted Oncology;2023-04-19

2. CDK4/6 inhibitor resistance: A bibliometric analysis;Frontiers in Oncology;2022-12-01

3. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1;Cell Communication and Signaling;2022-09-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP